Beth Israel Deaconess Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Beth Israel Deaconess Medical Center sits in the top decile of US sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count).
Beth Israel Deaconess Medical Center: 488 sponsored US clinical trials, 66 recruiting.
Beth Israel Deaconess Medical Center sponsors 488 registered US clinical trials on ClinicalTrials.gov, 66 of them currently recruiting, and 321 completed. 45 of these trials are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 8 trials.
Top-decile sponsor footprint
Beth Israel Deaconess Medical Center ranks in the top decile of sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
321 of 380 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
488 total, page 6 of 10
Pain Sensitization and Habituation in a Model of Experimentally-induced Insomnia Symptoms
NCT02484742
Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation
NCT02332096
Increasing Donor Designation Rates in Teenagers: Effectiveness of a Driver's Education Intervention
NCT03013816
Assessing Neurocognitive Effects of Gluten Exposure
NCT01506349
Pancreatic Enzyme Supplementation for Celiac Disease
NCT02475369
Prenatal Yoga for Pregnancy Related Back Pain
NCT03651232
Esmolol to Treat the Hemodynamic Effects of Septic Shock
NCT02369900
Mechanisms of Weight Loss With SGLT2 Inhibition
NCT02360774
Transcranial Stimulation for Essential Tremor
NCT03025529
Clinical Utility and Validation of the Rhythmia Mapping System for the Treatment of Cardiac Arrhythmias
NCT03094221
Challenging the Inflammatory Response System in Insomnia Disorder
NCT02261597
Thiamine as an Adjunctive Therapy in Cardiac Surgery
NCT02322892
Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation
NCT02339376
Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis
NCT02459210
Effect of Standardized Consent for Urogynecological Procedures on Patient Satisfaction
NCT02313701
Aerosol Inhalation Treatment for Dyspnea - Patients
NCT02524054
Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)
NCT03015272
Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer
NCT02275871
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
NCT02175225
Non-invasive Measurement of Brain Oxygen Levels in People With Subthalamic Deep Brain Stimulators
NCT02278406
Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms
NCT02268565
Neuromuscular Blockade for Post-Cardiac Arrest Care
NCT02260258
Trial of a Mammography Decision Aid for Women Aged 75 and Older
NCT02198690
Uniport and Multiport Epidural Catheters in Post-surgical Patients
NCT02159560
Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions
NCT02220205
UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation
NCT02178787
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
NCT01954979
A Trial of Lifestyle Interventions to Control Weight After Bariatric Surgery
NCT02603601
Mind Body Syndrome (MBS) Therapy for the Treatment of Chronic Pain
NCT02117921
Innovative Ultrasound Technology in Neuromuscular Disease
NCT02104921
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
NCT02118805
The Effect of Thiamine vs. Placebo on VO2 in Critical Illness
NCT01985685
The Effect of Linagliptin on Mitochondrial and Endothelial Function
NCT01969084
Statin Therapy in Acute Influenza
NCT02056340
Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
NCT01975909
Fostering Eating After Stroke With Transcranial Direct Current Stimulation
NCT01919112
The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery
NCT02146898
Celiac Disease Screening
NCT01902368
Pathogenic Mechanisms in C Diff Infection and Colitis
NCT01930032
Response to Supplement and Placebo in GERD
NCT01915173
House Calls and Decision Support: Improving Access to Live Donor Transplantation
NCT01786525
Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease
NCT01847170
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
NCT02322879
High-Dose Deferoxamine in Intracerebral Hemorrhage
NCT01662895
Immune Response in Celiac Disease on In-vitro Gluten Challenge
NCT01909050
A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation
NCT02664311
Lenalidomide After Allo Transplant
NCT01750762
Ischemic Conditioning in STEMI Patients
NCT03097419
Non-Invasive Shock: Differentiating Shock in the Emergency Department
NCT02164851
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
NCT01681225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 91 |
| Phase 3 | 13 |
| Phase 4 | 32 |
Therapeutic Areas
What is open in the Beth Israel Deaconess Medical Center pipeline
66 recruiting of 488 indexed (14% open); 321 completed (66%).
Phase mix: 45 late (III/IV) vs 144 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Beth Israel Deaconess Medical Center: open-pipeline peers nationwide
Peers matched on 488 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 488 trials (± recruiting share)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Case Comprehensive Cancer Center · 14% recruiting · 407 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Beth Israel Deaconess Medical Center page
488 registered trials is a research-attention snapshot, not an endorsement of Beth Israel Deaconess Medical Center or any single study.
- 66 of Beth Israel Deaconess Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Beth Israel Deaconess Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Beth Israel Deaconess Medical Center pipeline card: 488 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.